Personal tools

You are here: Home / Research / Non-Invasive Therapy & Drug Delivery / BUBBL People / Professor Constantin-C. Coussios

Professor Constantin-C. Coussios

Director, Oxford Institute of Biomedical Engineering, Statutory Chair of Biomedical Engineering, Professorial Fellow of Magdalen College

Professor Constantin-C. CoussiosContact

Email:
Phone: +44(0)1865 617 727
Mailing address: Institute of Biomedical Engineering, Old Road Campus Research Building, University of Oxford, Oxford OX3 7DQ, UK

Academic Background

Constantin Coussios is the Professor of Biomedical Engineering (Drug Delivery) and heads the Biomedical Ultrasonics, Biotherapy & Biopharmaceuticals Laboratory (BUBBL) in the  Oxford Institute of Biomedical Engineering . He is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3), supported by an EPSRC Programme grant. He holds a B.A., M.Eng., M.A. and Ph.D. from the University of Cambridge. During his time as an undergraduate and graduate student, Prof. Coussios was the recipient of the Shell European Project Prize (1997), the Greek State Graduate Scholarship (1999-2001), the Acoustical Society of America best student paper award (2001) and the Hamilton Prize (2001). He then had the opportunity to work as a post-doctoral researcher under some of the world's leading experts in acoustic cavitation, including Prof. C.K. Holland at the University of Cincinnati (Ohio, USA, 2001-02), on developing a novel ultrasound-enhanced thrombolysis system for stroke therapy, and Prof. R.A. Roy and Prof. R.G. Holt at Boston University (Mass, USA, 2002-03). He was awarded the 2002-2003 F.V. Hunt Post-Doctoral Fellowship in Acoustics by the Acoustical Society of America, given annually to a single researcher worldwide, which he devoted to investigating new means of cavitation detection in tissue and tissue-mimicking media during cancer treatment by High-Intensity Focussed Ultrasound. Prof. Coussios serves on the Acoustical Society’s Technical Committee on Biomedical Ultrasound and was elected to the Board of the International Society in Therapeutic Ultrasound in December 2006. In 2007, he was awarded the Institute of Acoustics Young Investigator Award for Innovation in Acoustical Engineering, and was selected as one of seven nationwide recipients of an EPSRC Challenging Engineering Award. In 2009, he was elected as the youngest Fellow of the Acoustical Society of America and, in 2012, the Society recognized his contributions to 'biomedical ultrasonics' with the R. Bruce Lindsay Award. He is also the recipient of the 2012 Frederic Lizzi award from the International Society for Therapeutic Ultrasound.

Awards and Prizes

  • Shell European Project Prize (1997)
  • Greek State National Scholarship (1998-2001)
  • ASA Best Student Paper Award (2001)
  • Hamilton Prize (2001)
  • ASA Hunt Post-Doctoral Fellowship in Acoustics (2002)
  • Institute of Acoustics Young Person’s Award for Innovation in Acoustical Engineering (2007)
  • EPSRC Challenging Engineering Award (2007)
  • Elected a Fellow of the Acoustical Society of America (2009)
  • R. Bruce Lindsay Award by the Acoustical Society of America (2012). 
  • Fred Lizzi Award by the International Society for Therapeutic Ultrasound (2012).
  • Royal Academy of Engineering Silver Medal (2017)
  • Elected a Fellow of the Royal Academy of Engineering (2019)
     

Translational Activities

  • OrganOx Ltd: In 2008, Prof. Coussios co-founded OrganOx Ltd with Professor Peter Friend, Chair of Transplantation at the University of Oxford, to develop a novel normothermic device for liver preservation and repair prior to transplantation. The company recently completed its Phase I clinical trial and is proceeding to randomised multi-centre Phase II/III trials in Europe and North America. 
  • OxSonics Ltd: In 2014, Prof. Coussios was the lead academic founder, with Professor Bob Carlisle and Dr Christian Coviello at the University of Oxford, of OxSonics Ltd, a company developing a new generation of ultrasound-based medical devices for bubble-enhanced (cavitational) drug delivery and minimally invasive surgery. The company is built on over 10 years of pre-clinical research and a portfolio of 10 patents from within BUBBL.


Selected Recent Publications